Nektar Therapeutics Inc

Most Recent

  • uploads///close up drugs medical medicine
    Company & Industry Overviews

    Wall Street Is Bullish on Nektar Stock despite Stock Price Slump

    Nektar is a development-stage biotechnology company that has a drug pipeline focused on the treatment of cancer, autoimmune diseases, and chronic pain.

    By Sarah Collins
  • uploads///Spectrum
    Company & Industry Overviews

    A Look at Spectrum’s Financial Position in September

    In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.

    By Daniel Collins
  • uploads///SRPT EPS
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Recent Developments

    In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    How Is Sarepta Therapeutics Positioned in January?

    In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.

    By Daniel Collins
  • uploads///virus _
    Company & Industry Overviews

    Sarepta Therapeutics Stock Rose 96% in 2018

    On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.

    By Daniel Collins
  • uploads///Spectrum
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Financial Overview in December

    In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.

    By Daniel Collins
  • uploads///syringe _
    Earnings Report

    How Nektar Performed in the Third Quarter

    Nektar Therapeutics generated total revenues of $27.76 million in the third quarter of 2018 as compared with $152.93 million in the third quarter of 2017.

    By Kenneth Smith
  • uploads///NKTR
    Company & Industry Overviews

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    Why Advaxis Stock Is Soaring Today

    Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22.

    By Daniel Collins
  • uploads///gAINERS
    Company & Industry Overviews

    Nektar Therapeutics Closed Higher on June 14

    Nektar Therapeutics, which is an American biopharmaceutical company, was the S&P 500’s top performer on June 14.

    By Val Kensington
  • uploads///gAINERS
    Company & Industry Overviews

    Top Gainers: Macy’s Rose on June 5

    On June 5, J.P. Morgan upgraded Macy’s target price from $35 to $41 and boosted the prices. On June 5, Macy’s gained 8% and closed the day at $40.05.

    By Val Kensington
  • uploads///NKTR
    Company & Industry Overviews

    Nektar’s Deals: Daiichi Sankyo, Ophthotech, Bristol-Myers Squibb

    Agreement with Daiichi Sankyo In May 2016, Nektar Therapeutics (NKTR) entered into a collaboration and licensing agreement with Daiichi Sankyo, under which Nektar granted exclusive commercialization rights for its product candidate, Onezeald, to Daiichi Sankyo in Europe. Onezeald is a long-acting topoisomerase-1 inhibitor in clinical development for treating adult patients with advanced breast cancer. Nektar […]

    By Kenneth Smith
  • uploads///Nektar Immuno Oncology Strategy
    Company & Industry Overviews

    A Deeper Look at Nektar Therapeutics’ Licensing Agreements

    License and collaboration agreements Nektar Therapeutics (NKTR) has entered into a number of licensing and collaboration agreements for research, development, and commercialization with various healthcare companies, including Eli Lilly (LLY), AstraZeneca (AZN), and Amgen (AMGN). Under these agreements, Nektar is entitled to receive license fees, milestone payments, royalties, and payments for manufacturing and supplying Nektar’s […]

    By Kenneth Smith
  • uploads///Nektar Analysts Reco
    Company & Industry Overviews

    Analysts’ Ratings for Nektar Therapeutics in January 2018

    San Francisco–based biopharmaceutical company Nektar Therapeutics (NKTR) develops drug candidates that make use of its advanced polymer conjugate technology platforms.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Nektar’s NKTR-358 Collaboration with Eli Lilly Boosted Revenues

    Nektar Therapeutics (NKTR) recognized $128 million of the $150 million upfront payment from Eli Lilly (LLY) related to the development of investigational drug NKTR-358.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.